| US Market Size | $282 MnIQVIA Estimates |
|---|---|
| Market Cap | ₹20,248.95 CrMid Cap |
| P/E TTM | 23.99Sector: 43.74 |
| 1-Year Return | 12.38%Price Performance |
Key highlights
- Final USFDA approval received for Binimetinib Tablets in 15 mg and 45 mg strengths
- Secured 180 days of generic drug exclusivity as a first-to-file applicant
- Targeting a US market size of approximately US$ 282 million as of September 2026
- Therapeutically equivalent to the reference drug Mektovi by Array BioPharma Inc.
- Cumulative USFDA approvals for the company now stand at 248 products
Strategic Approval for High-Value Oncology Generic
Alembic Pharmaceuticals Limited has secured final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Binimetinib Tablets. The approval covers the 15 mg and 45 mg strengths, which serve as a kinase inhibitor indicated for use in combination with encorafenib.
This combination therapy is used to treat adult patients with unresectable or metastatic melanoma or metastatic non-small cell lung cancer (NSCLC) that exhibits a BRAF V600E or V600K mutation. The product is a generic version of Mektovi Tablets, originally developed by Array BioPharma Inc., marking a key addition to Alembic's specialized oncology portfolio.
Exclusivity Status and Market Opportunity
- Alembic was one of the first ANDA applicants for the 15 mg dose and the sole first applicant for the 45 mg strength.
- The company is eligible for 180 days of generic drug exclusivity for both approved strengths.
- IQVIA data estimates the market size for Binimetinib tablets at US$ 282 million for the twelve months ending September 2026.
- The approval follows a Paragraph IV certification, indicating a challenge to existing patents for the reference drug.
- This launch contributes to the company's total count of 230 final USFDA approvals to date.
Strengthening US Portfolio Amid Robust Financial Growth
This regulatory milestone coincides with a period of significant financial expansion for the company. For the quarter ended September 30, 2026, Alembic reported a 36.3% year-on-year increase in operating revenue to ₹2,603.48 crore, while net profit grew 81.5% to ₹335.17 crore. The company maintains an operating profit margin of 21.64%, significantly higher than the 16.5% recorded four quarters ago.
On November 4, 2026, management raised its consolidated revenue growth guidance for FY27 to 20-25% and highlighted a pipeline of over 30 generic products planned for the US market over the next 18 months.
What to watch next
- Commercial launch of Binimetinib tablets in the US market to utilize the 180-day exclusivity period
- Execution of the 30+ generic product US pipeline guided by management on 04 Nov 2026
- Initial launches under the DifGen Pharmaceuticals collaboration expected to commence in FY28
- Next quarterly financial results announcement scheduled for early February 2027
| Share price | ₹1030.15 |
|---|---|
| Market capitalisation | ₹20,248.95 Cr |
| Revenue (annual) | ₹7,344.90 Cr |
| Net profit (annual) | ₹674.77 Cr |
| Revenue (latest quarter) | ₹2,603.48 Cr+21.11% vs previous quarter |
| Net profit (latest quarter) | ₹335.17 Cr+93.66% vs previous quarter |
| P/E (TTM) | 23.99×Sector 43.74× |
| Promoter holding | 69.87%0.00% QoQ |
| FII holding | 4.55%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Alembic Pharmaceuticals Limited announcing USFDA final approval for Binimetinib Tablets. Market figures from a third-party data provider.







